- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05617092
The Effect of a Postpartum Training Program on Women Who Have Suffered a Levator Ani Injury.
The Effect of a Postpartum Training Program on Women Who Have Suffered a Levator Ani Injury. A Pilot Randomized Controlled Trial Study
The goal of this pilot randomized pilot controlled trial (RTC)is to collect acceptability and feasibility outcomes of a physiotherapy individualized program in women with levator injury that is intended to be used in a larger scale multicenter randomized controlled trial (RTC) in the future. The main questions it aims to answer are if a physiotherapy program in women with a levator injury:
- Can improve the pelvic floor morphometry (PFM).
- Can improve urogynecological symptoms
- The effect of a physiotherapy program in the sexual function
- The effect of a physiotherapy program in the patient's fear avoidance beliefs about physical activity and work Type of study: randomized pilot controlled trial (RTC) The design of this trial will be a pilot randomized controlled trial with 3 arms. Participants will be randomized in 2 arm of women with levator ani injury to either physiotherapy or standard care and an arm of woman without levator injury Researchers will compare the 3 groups to see if a physiotherapy program have benefits in morphometry of the pelvic floor, urogynecological symptoms, sexual function and to avoid fear avoidance beliefs about physical activity and work.
Study Overview
Status
Intervention / Treatment
Detailed Description
The levator ani is a broad, thin muscle group, situated on either side of the pelvis. It supports the viscera in the pelvic cavity, and surrounds the various structures that pass through it. The levator ani muscles are of central importance in pelvic organ support and the maintenance of urinary and fecal continence. Vaginal delivery was associated with a higher number of pelvic floors injury at different levels (10% to 30% of women with vaginal deliveries). One of these specific types of pelvic floor injury include levator avulsion muscle (LAM) and levator ballooning. International clinical guidelines in agreement with meta-analysis recommend pelvic floor muscle (PFM) physiotherapy as a first line treatment for symptoms related to postpartum injuries. However, it is unclear whether women with levator ani injury lesions could respond to physiotherapy. There have been no randomized studies on this matter and the pilot studies have focused on anatomy rather than symptoms.
Trial Design A randomized pilot-controlled trial is designed to collect acceptability and feasibility outcomes of a physiotherapy individualized program in women with levator ani injury that is intended to be used in a larger scale multicenter randomized controlled trial in the future.
Methods The design of this trial will be a pilot randomized controlled trial with 3 arms:2 randomized arm of women with levator ani injury to either physiotherapy or standard care and an arm of woman without levator injury Participants Assessed for eligibility will be primiparous with a simplex vaginal delivery, aged ≥18 years, that understands the Swedish language, who approve vaginal examinations and with known risk factors for avulsion (instrumental delivery, maternal age >35 years, prolonged or precipitous second stage, and fetal occipito-posterior position).
10-12 weeks after the delivery a clinical 3 D ultrasound of pelvic floor will be perform.
Women with an injury in the levator ani will be randomized into two groups, one for intervention and the other for control.
Interventions The intervention group will receive a physiotherapy individualized treatment according to the needs of the patient and clinical findings and symptoms with the information provided by the employed questionnaires and clinic exploration.
Physiotherapy treatment will start from 3 months postpartum to about 1 year after The control group will receive general information according to the postpartum care guidelines of the region ( Västrä Gotaland Regionen).
Objective
The main objectives of this pilot study will be to evaluate the effect of a physiotherapy program in women with a levator ani injury:
- To demonstrate the feasibility of conducting a trial to evaluate the intervention, including the feasibility and acceptability of randomising the intervention and the feasibility of outcome measure collection.
- To improve the pelvic floor muscle morphometry.
- To improve the urogynecological symptoms.
- To improve the sexual function.
- To improve the patient's fear avoidance beliefs about physical activity. Outcome Morphometrics variables as Pelvic Organ Prolapse Quantification Examination (POP-Q) Modified Oxford Grading System and Ultrasound variables: External an external sphincter, Levator hiatus area at rest (cm2),during Valsalva (cm2) and at maximum contraction (cm2) LAM area (cm2), Right and left puborectal muscle thickness (mm) will be collect.
The followed questionnaires will be use: Pelvic Floor Impact Questionnaire (PFIQ-7), Pelvic Floor Distress Inventory-20 (PFDI-20), Fear Avoidance Beliefs Questionnaire (Physical Activity/PA) and Female Sexual Function Index FSFI-19.
Feasibility of recruitment will be assessed by exploring: the number of those referred to the trial over the study period, who meet the eligibility criteria, the number of eligible patients who consent to participate in the trial over the study period,the number of patients who decline to participate, the number of participants who consent to participate that remain in the trial after 4-month follow-up, the number/proportion of participants with complete baseline data over the study period, the number/proportion of participants with complete follow-up data at 4 months follow-up, the number/proportion of participants retained at the end of each module of treatment.
Randomization Women with an injury in the levator found in the ultrasound will be randomized with a computer program into two groups, one for intervention and the other for control A group of women without injury will be invited to filling in the questionnaires that will be carried out in the study three, six months and one year postpartum.
Blinding Ultrasound diagnosis of levator ani muscle injury will be determined by 2 gynecologists blinded to delivery outcomes, using validated protocols. Women with levator ani injury will be randomly assigned to one of two groups: one (Intervention), and the other (the comparison group) receiving conventional recommendations.
The investigator assessing outcome will be blinded to treatment allocation.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rocio Montejo, PhD
- Phone Number: +46104352244
- Email: rocio.montejo.rodriguez@vgregion.se
Study Locations
-
-
-
Trollhättan, Sweden
- Recruiting
- Nu sjukvård
-
Contact:
- Rocio Montejo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- simplex vaginal first delivery with a elevator ani injury
- aged ≥18 years
- understands the Swedish language in speech and writing
- approves vaginal examination
Exclusion Criteria:
- diagnosed sphincter injury grade 3-4
- serious postpartum disease (heart failure, thrombophlebitis, recent pulmonary embolism, acute infectious disease, genital haemorrhage, severe hypertension, dyspnoea, severe anemia or severe mental illness)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
intervention group will receive a physiotherapy individualized treatment
|
physiotherapy individualized treatment according to the needs of the patient and clinical findings and symptoms
|
No Intervention: Control Group
No intervention in women with injury in the levator ani
|
|
No Intervention: Healthy controls
A group of women without injury that will be invited to filling in the questionnaires that will be carried out in the study three, six months and one year postpartum.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of the trial.
Time Frame: 4 months after delivery
|
The number of those referred to the trial over the study period, who meet the eligibility criteria, the number of eligible patients who consent to participate in the trial over the study period, and the number of patients who decline to participate, the number of participants who consent to participate that remain in the trial by 4-month follow-up, the number/proportion of participants with complete baseline data over the study period, the number/proportion of participants with complete follow-up data at 4 months follow-up, the number/proportion of participants retained at the end of each module of treatment.
|
4 months after delivery
|
Feasibility of the trial.
Time Frame: 6 months after delivery
|
The number of those referred to the trial over the study period, who meet the eligibility criteria, the number of eligible patients who consent to participate in the trial over the study period, and the number of patients who decline to participate, the number of participants who consent to participate that remain in the trial by 4-month follow-up, the number/proportion of participants with complete baseline data over the study period, the number/proportion of participants with complete follow-up data at 4 months follow-up, the number/proportion of participants retained at the end of each module of treatment.
|
6 months after delivery
|
Feasibility of the trial.
Time Frame: 12 months after delivery
|
The number of those referred to the trial over the study period, who meet the eligibility criteria, the number of eligible patients who consent to participate in the trial over the study period, and the number of patients who decline to participate, the number of participants who consent to participate that remain in the trial by 4-month follow-up, the number/proportion of participants with complete baseline data over the study period, the number/proportion of participants with complete follow-up data at 4 months follow-up, the number/proportion of participants retained at the end of each module of treatment.
|
12 months after delivery
|
Morphometry with ultrasound Area
Time Frame: 10-12 weeks after delivery
|
3-D Ultrasound examination., Levator hiatus area at rest (cm2),during Valsalva (cm2) and at maximum contraction (cm2)
|
10-12 weeks after delivery
|
Morphometry with ultrasound Area
Time Frame: 12 months after delivery
|
3-D Ultrasound examination., Levator hiatus area at rest (cm2),during Valsalva (cm2) and at maximum contraction (cm2)
|
12 months after delivery
|
Morphometry with ultrasound Levator urethra GAP (LUG)
Time Frame: 10-12 weeks after delivery
|
The distance between the center of the urethra and the levator insertion (LUG) in cm
|
10-12 weeks after delivery
|
Morphometry with ultrasound Levator urethra GAP (LUG)
Time Frame: 12 months after delivery
|
The distance between the center of the urethra and the levator insertion (LUG) in cm
|
12 months after delivery
|
Morphometry with ultrasound muscle thickness
Time Frame: 10-12 weeks after delivery
|
Right and left puborectal muscle thickness (mm) .
|
10-12 weeks after delivery
|
Morphometry with ultrasound muscle thickness
Time Frame: 12 months after delivery
|
Right and left puborectal muscle thickness (mm) .
|
12 months after delivery
|
Urogynecological symptoms.
Time Frame: 3 months after delivery
|
Pelvic Floor Impact Questionnaire (PFIQ-7)
|
3 months after delivery
|
Urogynecological symptoms.
Time Frame: 6 months after delivery
|
Pelvic Floor Impact Questionnaire (PFIQ-7)
|
6 months after delivery
|
Urogynecological symptoms.
Time Frame: 12 months after delivery
|
Pelvic Floor Impact Questionnaire (PFIQ-7)
|
12 months after delivery
|
Urogynecological symptoms.
Time Frame: 3 months after delivery
|
Pelvic Floor Distress Inventory-20 (PFDI-20)
|
3 months after delivery
|
Urogynecological symptoms.
Time Frame: 6 months after delivery
|
Pelvic Floor Distress Inventory-20 (PFDI-20)
|
6 months after delivery
|
Urogynecological symptoms.
Time Frame: 12 months after delivery
|
Pelvic Floor Distress Inventory-20 (PFDI-20)
|
12 months after delivery
|
Physics activity level.
Time Frame: 3 months after delivery
|
Open questions on Physics activity level.
|
3 months after delivery
|
Physics activity level.
Time Frame: 6 months after delivery
|
Open questions on Physics activity level.
|
6 months after delivery
|
Physics activity level.
Time Frame: 12 months after delivery
|
Open questions on Physics activity level.
|
12 months after delivery
|
Sexual Function.
Time Frame: 3 months after delivery
|
Female Sexual Function Index FSFI-19 questionnaire
|
3 months after delivery
|
Sexual Function.
Time Frame: 6 months after delivery
|
Female Sexual Function Index FSFI-19 questionnaire
|
6 months after delivery
|
Sexual Function.
Time Frame: 12 months after delivery
|
Female Sexual Function Index FSFI-19 questionnaire
|
12 months after delivery
|
Fear Avoidance Beliefs Questionnaire (Physical Activity/PA)
Time Frame: 3 months after delivery
|
Fear-Avoidance Beliefs Questionnaire
|
3 months after delivery
|
Fear Avoidance Beliefs Questionnaire (Physical Activity/PA)
Time Frame: 6 months after delivery
|
Fear-Avoidance Beliefs Questionnaire
|
6 months after delivery
|
Fear Avoidance Beliefs Questionnaire (Physical Activity/PA)
Time Frame: 12 months after delivery
|
Fear-Avoidance Beliefs Questionnaire
|
12 months after delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pelvic Organ Prolapse Quantification Examination (POP-Q)
Time Frame: 10-12 weeks after delivery
|
assessing the degree of prolapse of pelvic organs to help standardize diagnosing, comparing, documenting, and sharing of clinical findingsThe prolapsed organs will be measured in centimeters to the hymen
|
10-12 weeks after delivery
|
Pelvic Organ Prolapse Quantification Examination (POP-Q)
Time Frame: 12 months after delivery
|
assessing the degree of prolapse of pelvic organs to help standardize diagnosing, comparing, documenting, and sharing of clinical findingsThe prolapsed organs will be measured in centimeters to the hymen
|
12 months after delivery
|
Age
Time Frame: 10-12 weeks after delivery
|
Age in years
|
10-12 weeks after delivery
|
Body mass index (BMI)
Time Frame: 10-12 weeks after delivery
|
BMI is defined as the body mass divided by the square of the body height, and is expressed in units of kg/m2
|
10-12 weeks after delivery
|
Body mass index (BMI)
Time Frame: 12 months after delivery
|
BMI is defined as the body mass divided by the square of the body height, and is expressed in units of kg/m2
|
12 months after delivery
|
Weight gain during pregnancy
Time Frame: 10-12 weeks after delivery
|
Weight gain during pregnancy in kilograms
|
10-12 weeks after delivery
|
Delivery mode
Time Frame: 10-12 weeks after delivery
|
Delivery mode:vaginal delivery, forceps delivery or vacuum delivery
|
10-12 weeks after delivery
|
Baby's birth weight
Time Frame: 10-12 weeks after delivery
|
Baby's birth weight in kilograms
|
10-12 weeks after delivery
|
Previous abdominal operation
Time Frame: 10-12 weeks after delivery
|
Number of previous abdominal operation
|
10-12 weeks after delivery
|
Gastric bypass
Time Frame: 10-12 weeks after delivery
|
Gastric bypass surgery
|
10-12 weeks after delivery
|
Modified Oxford Grading Scale
Time Frame: 10-12 weeks after delivery
|
The modified Oxford Grading Scale [4] quantifies pelvic floor muscle strength as: 0, no contraction; 1, flicker; 2, weak; 3, moderate; 4, good; and 5, strong.
|
10-12 weeks after delivery
|
Modified Oxford Grading Scale
Time Frame: 6 months after delivery
|
The modified Oxford Grading Scale [4] quantifies pelvic floor muscle strength as: 0, no contraction; 1, flicker; 2, weak; 3, moderate; 4, good; and 5, strong.
|
6 months after delivery
|
Modified Oxford Grading Scale
Time Frame: 12 months after delivery
|
The modified Oxford Grading Scale [4] quantifies pelvic floor muscle strength as: 0, no contraction; 1, flicker; 2, weak; 3, moderate; 4, good; and 5, strong.
|
12 months after delivery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rocio Montejo, PhD, Vastra Gotaland Region
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 278806
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pelvic Floor Disorders
-
University Hospitals of North Midlands NHS TrustActive, not recruitingPelvic Floor DysfunctionUnited Kingdom
-
Peking UniversityActive, not recruitingPelvic Floor DysfunctionChina
-
Columbia UniversityUniversity of Wisconsin, Madison; University of Calgary; University of Arkansas; The Methodist Hospital Research InstituteCompleted
-
Assiut UniversityWithdrawn
-
Peking Union Medical College HospitalThe First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaboratorsRecruiting
-
Cathay General HospitalCompleted
-
Federal University of UberlandiaCompleted
-
Universitat Autonoma de BarcelonaCompleted
-
University of Sao PauloCompleted
-
Peking Union Medical College HospitalNot yet recruitingPelvic Floor Dysfunction
Clinical Trials on Physiotherapy treatment
-
Rigshospitalet, DenmarkThe Association of Danish Physiotherapists Research Fund, Denmark; The Jubilee...CompletedTrismus | Oropharyngeal Cancer | Oral Cavity Carcinoma | Adverse Effect of Radiation TherapyDenmark
-
Catholic University, ItalyUnknownCerebral Palsy
-
University of OviedoCompletedParkinson Disease
-
University of CadizCompleted
-
Clalit Health ServicesCompletedLow Back Pain | SciaticaIsrael
-
Rabin Medical CenterBeit-Rivka Geriatric Rehabilitation HospitalUnknown
-
University of MelbourneNational Health and Medical Research Council, AustraliaCompleted
-
Universidade Federal do Oeste do ParaFundação Amazônia de Amparo a Estudos e Pesquisas FAPESPACompleted
-
Ahmed Mohamed AbdelraufCompletedEdema Due to Obstruction of Lymph Vessels or Excision of Lymph NodesEgypt
-
Afridi Medical ComplexCompletedPulmonary Disease | COPDPakistan